Chiesi Total CareSM AND patient support

Photo of a smiling woman in a white lab coat
Chiesi Total CareSM logo

Chiesi Total Care is a comprehensive support program that provides exceptional service to patients and healthcare providers

A single call to your dedicated Chiesi Total Care team is all it takes, and they will guide you through the process of getting a patient started on MYCAPSSA therapy. The Chiesi Total Care program provides assistance to patients with or without commercial insurance, Medicaid, and Medicare.*

image of Assess patient eligibility, Insurance Assistance and Access to medication
image of Assess patient eligibility, Insurance Assistance and Access to medication
*Please refer to the full Terms and Conditions for additional eligibility requirements.
Patients May Pay as Little as $0 for Their MYCAPSSA Prescription
To be eligible for these programs:
  • Patient must be enrolled in Chiesi Total Care. (Enrollment and Authorization Form will be mailed to your patient’s home)
  • Patient must have commercial insurance and a valid prescription for a US FDA-approved indication for MYCAPSSA
  • Patient must be a resident of the United States or one of its territories
$0 out of pocket* $0 out of pocket*
For more information about ordering MYCAPSSA, contact Chiesi Total Care
chiesitotalcare.com
1-833-346-2277
Watch MYCAPSSA Patient Stories
Jim thumbnail
Jim's story of hope
Watch Jim as he talks about life with MYCAPSSA, and the support he's received along the way. Listen as he encourages others with acromegaly to advocate for themselves.

Resources for You and to Share With Your Patients for Acromegaly Support

Frequently Asked Questions About MYCAPSSA

MYCAPSSA is an oral somatostatin analog approved for the long-term maintenance treatment of acromegaly in patients who have responded to and tolerated treatment with octreotide or lanreotide.1

Patients who respond to and tolerate octreotide or lanreotide may be eligible to take MYCAPSSA instead of receiving injections.2

If your patient’s current SSA treatment is effective and tolerable, he or she may be eligible to take oral MYCAPSSA capsules instead of receiving monthly injections.1,2

The most common side effects of MYCAPSSA are headache, joint pain, nausea, weakness, diarrhea, and excessive sweating.1 Learn more about possible side effects in our safety profile.

MYCAPSSA is an oral octreotide formulation. MYCAPSSA uses Transient Permeability Enhancer (TPE®), a cutting–edge technology that allows octreotide to be given as an oral treatment.1,3 You can learn more about TPE and how MYCAPSSA works here.

Yes, MYCAPSSA was proven to effectively maintain normal IGF-I and growth hormone levels in the majority of patients.1,4 Learn more about consistent control and the proven benefits of MYCAPSSA here.

GH, growth hormone; IGF-I, insulin-like growth factor 1.

Once MYCAPSSA has been started, evaluate IGF-I, signs, and symptoms, and titrate MYCAPSSA as needed.1 Majority of patients in clinical trials received a 60–mg dose of MYCAPSSA or higher.4-6 Once the maintenance dosage of MYCAPSSA is achieved, monitor IGF-I levels and acromegaly signs and symptoms monthly.1 Encourage patients to keep an open dialogue about how they feel and any potential symptoms they may experience.1

MYCAPSSA should be taken twice daily, morning and evening. MYCAPSSA should be taken on an empty stomach (1 hour before or 2 hours after a meal) with a glass of water.1 See dosing information here.

If a patient forgets to take their dose of MYCAPSSA, he or she should not take the missed dose at a later time.7 Advise the patient to take the next dose at the scheduled time.7 Encourage patients to be open and honest about any difficulties they experience in taking regular doses.

MYCAPSSA will be delivered monthly to your patient’s home or designated location. The Chiesi Total CareSM team will work with your patient to deliver MYCAPSSA when and where it’s most convenient for them. Your patient should receive a call from the pharmacy to confirm the shipment. Learn more about Chiesi Total Care.

Commercially insured patients can get MYCAPSSA for as little as $0 out of pocket, based on eligibility. The Chiesi Total CareSM team is here to guide your office and your patients through the process of getting patients started on MYCAPSSA therapy. For more information and for help understanding how MYCAPSSA works with your patient’s insurance plan, call 1-833-346-2277, Monday–Friday, 7:00 AM-7:00 PM CST.

Amryt Assist is now Chiesi Total CareSM. The Chiesi Total Care team will be there every step of the way to help make accessing, starting, and staying on MYCAPSSA treatment as easy as possible. They will help facilitate communication between your office, your patient, their specialty pharmacy, and their insurance company to make the transition to MYCAPSSA as seamless as possible. Learn more about Chiesi Total Care.

Yes! Your patient’s specialty pharmacy will help them stay on track with their refills of MYCAPSSA. The pharmacy will reach out each month to coordinate a convenient delivery time for each refill. If any questions or issues arise, your office or your patient can always contact the Chiesi Total CareSM team for further assistance.

Before first use, unopened wallets of MYCAPSSA should be stored in a refrigerator. Be sure not to freeze MYCAPSSA. After the first use for each wallet, opened wallets can be stored at room temperature between 68°F to 77°F (20°C to 25°C) for up to one month. Care should be taken to keep MYCAPSSA in a safe place and always out of the reach of children.1

MYCAPSSA is an oral form of octreotide, taken twice a day.1

Somavert® (pegvisomant for injection) is a subcutaneous injection, self-administered once daily after a physician-supervised initial loading dose.8 Somatuline® Depot (lanreotide) is for deep subcutaneous injection only, initially administered every 4 weeks by a healthcare professional.9 Sandostatin® LAR Depot (octreotide acetate) and Signifor® LAR (pasireotide) are intramuscular injections, administered monthly by a healthcare professional.10,11

Patients who respond to and tolerate octreotide or lanreotide may be eligible to take MYCAPSSA.

Somavert® is a registered trademark of Pfizer Inc.
Somatuline Depot is a registered trademark of Ipsen Pharma S.A.S.
§Sandostatin® is a registered trademark of Novartis Pharmaceuticals Corporation.
||Signifor® is a licensed trademark of Recordati Rare Diseases Inc.
Please refer to the full Prescribing Information for each product for full Dosage and Administration information.

Chiesi Global Rare Diseases: Our commitment

Chiesi Global Rare Diseases is committed to helping address wellness within the rare disease community

We strive to provide unmatched support in the lives of people living with rare diseases. We work in close partnership with caregivers, patient communities, healthcare professionals, government authorities, and other stakeholders to help make an impact in the rare disease community. We relentlessly pursue sustainable development goals with passion, courage, teamwork, and innovation. We believe—from timely and accurate diagnoses to receiving treatments and finding supportive communities—that no one should feel alone.

Learn more about Chiesi Global Rare Diseases
Chiesi logo Chiesi logo
REFERENCES: 1. MYCAPSSA [package insert]. Amryt Pharmaceuticals; 2022. 2. Fleseriu M, et al. Pituitary. 2021;24:1-13. 3. Tuvia S, et al. Pharm Res. 2014;31(8):2010-2021. 4. Melmed S, et al. J Clin Endocrinol Metab. 2015;100(4):1699-1708. 5. Fleseriu M, et al. Lancet Diabetes Endocrinol. 2022;10(2):102-111. 
6. Samson SL, et al. J Clin Endocrinol Metab. 2020;105(10):1-13. 7. Octreotide. MedlinePlus. Updated September 14, 2020. Accessed November 21, 2023. https://medlineplus.gov/druginfo/meds/a620051.html 8. Somavert [package insert]. Pfizer Inc; 2021. 9. Somatuline Depot [package insert]. Ipsen Biopharmaceuticals Inc; 2019. 10. Sandostatin LAR Depot [package insert]. Novartis Pharmaceuticals Corp; 2021. 11. Signifor LAR for injectable suspension, for intramuscular use [package insert]. Recordati Rare Diseases Inc; 2020.

Important Safety Information

CONTRAINDICATIONS

Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

WARNINGS AND PRECAUTIONS

MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

ADVERSE REACTIONS

The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS

The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.

PREGNANCY

Advise premenopausal females of the potential for an unintended pregnancy.

Please contact Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including Medication Guide.


Indication

INDICATION AND USAGE

MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

Important Safety Information

CONTRAINDICATIONS

Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

WARNINGS AND PRECAUTIONS

MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected.

Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly.

Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

ADVERSE REACTIONS

The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

DRUG INTERACTIONS

The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA.

Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA.

PREGNANCY

Advise premenopausal females of the potential for an unintended pregnancy.

Please contact Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including Medication Guide.


Indication

INDICATION AND USAGE

MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.